It is hard to believe that only 3 short years ago today on August 18th, 2015, we launched the Virta Treatment by enrolling our first clinical trial patient. Amazingly, it was only the night before that our small team of 10 people in San Francisco had finalized the first version of the software that would enable the continuous remote care required to deliver diabetes reversal.
Simultaneously, our research team was manually (and frantically, to be sure) packing Virta patient starter kits in Lafayette, IN, and making final preparations to welcome our first patients.
Our protocols, built on decades of research by Virta co-founders Drs. Stephen Phinney and Jeff Volek, were ready. In the context of a new care model to treat type 2 diabetes, though, there was uncertainty. Would it scale? Would the results be sustainable? We were confident, but no one really knew.
Fast forward three years and we can now acknowledge the clarity we’ve brought to this question and how far we have come. We have:
As a company, we believe it is important to celebrate accomplishments. Yet, we tend not to dwell on any one thing for too long—if you look at the diabetes landscape, you quickly see how much work there is to do.
What never gets old, though, is celebrating the successes of our wonderful and rapidly growing group of patients. Each one has inspired us to do more, while teaching us about perseverance and that getting healthy isn’t about improving numbers, eliminating medications, or even saving money. It’s about so much more:
Anniversaries of any sort are a time to reflect, reassess, and set the course for the future. Our story, like those of so many of our future patients, is still largely unwritten. We are grateful for everyone who has helped us along the way, and for each of the individuals we’ve been able to serve in turn. Looking forward, we can’t wait until the day where we can say type 2 diabetes is a thing of the past.
Yet, we know this is a long way off. This might be our 3rd anniversary, but it’s still Day One at the office, and time to get back to our mission of reversing type 2 diabetes in 100 million people by 2025.